LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
企業コードLNSR
会社名LENSAR Inc
上場日Sep 21, 2020
最高経営責任者「CEO」Mr. Nicholas T. (Nick) Curtis
従業員数140
証券種類Ordinary Share
決算期末Sep 21
本社所在地2800 Discovery Drive
都市ORLANDO
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号32826
電話番号18885367271
ウェブサイトhttps://www.lensar.com/
企業コードLNSR
上場日Sep 21, 2020
最高経営責任者「CEO」Mr. Nicholas T. (Nick) Curtis
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし